Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Cash from Financing Activities data on record, last reported at $94.9 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 121.1% year-over-year to $94.9 million; the TTM value through Sep 2025 reached $240.5 million, up 165.99%, while the annual FY2024 figure was $134.9 million, 269.34% up from the prior year.
  • Cash from Financing Activities reached $94.9 million in Q3 2025 per TNXP's latest filing, up from $11.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $94.9 million in Q3 2025 and bottomed at -$11.5 million in Q1 2023.
  • Average Cash from Financing Activities over 3 years is $29.7 million, with a median of $11.0 million recorded in 2025.
  • The widest YoY moves for Cash from Financing Activities: up 23464.62% in 2025, down 56.48% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $40.7 million in 2023, then skyrocketed by 109.15% to $85.2 million in 2024, then grew by 11.4% to $94.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $94.9 million in Q3 2025, $11.0 million in Q2 2025, and $49.5 million in Q1 2025.